Novel mutations relating to x-linked charcot-marie-tooth disease
CA 2633281 C · Owner: Boss, Michael A. · Inventors: Ananth, Uma; Sullivan, Charleen M.; Seltzer, William K.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Specific mutations in the connexin-32 gene that are associated with X- linked Charcot-Marie-Tooth (CMT) disease are disclosed. Methods of diagnosing X-linked CMT disease are also disclosed. Methods include hybridization analysis such as Southern or Northern analysis, which use hybridization of mutant connexin- 32 nucleic acid probes to connexin-32 genes; direct mutation analysis by restriction digest; sequencing of the connexin-32 gene; hybridization of an allele- specific oligonucleotide with genomic DNA; or identification of mutant connexin-32 proteins. Mutant connexin-32 nucleic acid probes are also disclosed. The mutant connexin-32 nucleic acid probes have a mutation in at least one of …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 12, 1999 and granted February 28, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 12, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 12, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.